Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.50 |
| ▸ | MGLL | Q99685 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345040 | 0.79 | MAPT (0.61) | MGLLALDH1A1LMNAMAPTHPGD | |
| SCHEMBL3185016 | 0.79 | MGLL (0.50) | ARMGLLFAAH | |
| SCHEMBL10584544 | 0.76 | TLR9 (0.53) | MGLLALDH1A1HTTNPSR1FAAH | |
| SCHEMBL632634 | 0.76 | AR (0.67) | AR | |
| SCHEMBL10587456 | 0.76 | MGLL (0.57) | MGLLALDH1A1LMNAMAPTHPGD | |
| SCHEMBL1363039 | 0.75 | AR (0.63) | AR | |
| SCHEMBL15758697 | 0.74 | MGLL (0.59) | MGLLALDH1A1LMNAMAPTHPGD | |
| SCHEMBL8005849 | 0.74 | PKM (0.58) | MGLLALDH1A1LMNAMAPTHPGD | |
| SCHEMBL30198527 | 0.74 | PKM (0.58) | MGLLALDH1A1LMNAMAPTHPGD | |
| SCHEMBL15758246 | 0.74 | MGLL (0.53) | MGLLALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067582-B2 | Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQIOBB COMPANY | 2010-12-30 | — | — | US | disclosed |
| EP-2170899-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687881-A | Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO | 2010-03-31 | — | — | CN | disclosed |
| WO-2009003077-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | NR5A1, AR, ESRRA | AR 2/4885MGLL 4262/4885ALDH1A1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.